c-LEcta operates as a biotechnology company focusing on enzyme engineering and bioprocess development for regulated markets such as food and pharmaceutical. It develops, manufactures, and commercializes application-oriented enzyme variants either as its own product or in cooperative development with industry partners. c-LEcta offers DENARASE, agenetically engineered endonuclease used in biotechnology for the quantitative removal of nucleic acids and viscosity reduction; and CalB Immo Plus, a hydrophobic immobilized CalB preparation. Marc Struhalla and Thomas Greiner-Stöffele founded it in 2004, with its headquarters in Leipzig in Germany.

Pharmaceutical

Biotechnology

c-LEcta GmbH

Dr. Marc Struhalla

Kamila Rzeznicka

Patrick Hapke

Carsten Fietz

Nicole Albrecht

Dr. Michael Dirkmann

Christine Merten

Pierre Aldag

Tjebbe van der Meer

Heike Kutschke

Arlett Merkel

Raphael Gübeli

Andreas Vogel

Arnd Knoll

Mathias Bell

Andreas Buthe

The Sales and Business Development team at c-LEcta GmbH is responsible for identifying business opportunities, establishing strategic partnerships, and driving sales growth for the company's enzyme-based products. The team collaborates closely with industry partners in the food and pharmaceutical sectors to commercialize innovative enzyme variants, ensuring market penetration and customer satisfaction.

Sales and Business Development

Research and Development

Leadership Team

Sales and Business Development

About

Team members

Other teams at c-LEcta GmbH

Research and Development

Leadership Team